MET — MetLife, Inc.

MetLife Q3 2025 Earnings Call Summary

1. Key Financial Results and Metrics

• Adjusted Earnings: $1.6 billion, or $2.34 per share (up 21% year-over-year), with notable items totaling $18 million or $0.03 per share.
• Variable Investment Income: $483 million, exceeding the quarterly outlook of $425 million, driven by a 3% return in private equity.
• Adjusted Return on Equity: 16.7%, aligning with the target range of 15% to 17%.
• Direct Expense Ratio: 11.6%, below the full-year target of 12.1%, reflecting improved operational efficiency.
• Shareholder Returns: Approximately $875 million returned to shareholders through dividends and share repurchases in Q3.

2. Strategic Updates and Business Highlights

• New Frontier Strategy: Continued positive impact observed, particularly in Group Benefits and Retirement Income Solutions (RIS).
• Group Benefits: Adjusted earnings of $457 million (up 6%), with improved underwriting results in disability and dental.
• Retirement and Income Solutions: Adjusted earnings of $423 million (up 15%), with strong growth in structured settlements and longevity reinsurance.
• Asia Performance: Adjusted earnings of $473 million (up 36%), with sales growth of 34% driven by strong performance in Japan, Korea, and China.
• Latin America: Adjusted earnings of $222 million (up 2%), with continued momentum in Mexico, Chile, and Brazil.
• Chariot Re Launch: A strategic reinsurance partnership that enhances liability origination capacity.

3. Forward Guidance and Outlook

• Pension Risk Transfer (PRT): Anticipated record performance in Q4 with $12 billion of PRT transactions already secured.
• Expense Management: Expectation to maintain a direct expense ratio below 12.1% in Q4, aided by technology investments and operational efficiencies.
• Long-term Growth: Positive outlook for PRT business, with 94% of pension plan sponsors indicating plans to derisk portfolios within five years.

4. Bad News, Challenges, or Points of Concern

• Tax Law Change in Mexico: A notable charge of $71 million related to VAT deductions on health insurance claims, expected to impact earnings in 2025 and 2026, with a projected reduction of $50 million to $60 million in adjusted earnings for 2026.
• Group Benefits Underwriting: Group life mortality ratio was 83.3%, below the target range of 84% to 89%, indicating potential underwriting pressures.
• Market Competition: Competitive pressures remain in the Group Benefits market, though pricing is described as rational.

5. Notable Q&A Insights

• Asia Sales Momentum: Strong sales growth attributed to new product launches and enhancements, with expectations to exceed full-year sales guidance for 2025.
• PRT Market Dynamics: Record PRT transactions driven by MetLife's competitive advantages in the jumbo end of the market, emphasizing financial strength and risk management.
• Expense Seasonality: Anticipated increase in expenses in Q4, but overall efficiency gains expected to keep the direct expense ratio below targets.
• Private Credit Investing: MetLife maintains a disciplined approach to credit quality, focusing on high-quality investments amidst concerns about ratings inflation in the market.

Overall, MetLife's Q3 2025 results reflect strong operational performance and strategic execution, with some challenges ahead, particularly related to regulatory changes and competitive pressures in certain segments.